A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: MK-1708

Study type: Interventional

Funder types: Industry

Identifiers

NCT06647628

1708-005

Details and patient eligibility

About

The purpose of this study is to learn about the safety of MK-1708, and how well elderly people tolerate it. The study will also measure what happens to MK-1708 in a healthy elderly person's body over time (pharmacokinetic or PK study). Researchers will learn if at least 1 dose level of MK-1708 will be safe, well-tolerated, and will be above a certain level in people's blood after 24 hours.

Enrollment: 16 patients

Sex: All

Ages: 65 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

• Is in good health before randomization
• Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive

Exclusion criteria

The key exclusion criteria include but are not limited to the following:

• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Has a history of cancer (malignancy). Participants with definitively treated disease who, in the opinion of the study investigator, are highly unlikely to have a recurrence for the duration of the study may be enrolled at the discretion of the investigator

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

16 participants in 3 patient groups, including a placebo group

MK-1708 Dosage 1

Experimental group

Description:

Participants receive multiple doses of MK-1708 dosage 1.

Treatment:

Drug: MK-1708

MK-1708 Dosage 2

Experimental group

Description:

Participants receive multiple doses of MK-1708 dosage 2.

Treatment:

Drug: MK-1708

Placebo

Placebo Comparator group

Description:

Participants receive multiple doses of placebo.

Treatment:

Drug: Placebo